| 1. |
- Ohlsson, Jonas, et al.
(författare)
-
Co-digestion of salix and manure for biogas: importance of clone choice, coppicing frequency and reactor setup
- 2020
-
Ingår i: Energies. - : MDPI AG. - 1996-1073. ; 13
-
Tidskriftsartikel (refereegranskat)abstract
- Animalmanure represents amajor source of renewable energy that can be converted into biogasusing anaerobic digestion. In order to most efficiently utilize this resource, it can be co-digested withenergy dense, high biomethanation potential feedstocks such as energy crops. However, such feedstockstypically require pretreatments which are not feasible for small-scale facilities.We investigated theuse of single-stage and the sequential co-digestion of comminuted but otherwise non-pretreated Salixwith animal manure, and further investigated the effects of coppicing frequency and clone choice onbiomethanation potential and the area requirements for a typical Swedish farm-scale anaerobic digesterusing Salix and manure as feedstock. In comparison with conventional single-stage digestion, sequentialdigestion increased the volumetric and specific methane production by 57% to 577 NmL L?1 d?1 and192 NmL (g volatile solids (VS))?1, respectively. Biomethanation potential was the highest for the twoyear-old shoots, although gains in biomass productivity suggest that every-third-year coppicing maybe a better strategy for supplying Salix feedstock for anaerobic digestion. The biomethane productionperformance of the sequential digestion of minimally pretreated Salix mirrors that of hydrothermallypretreated hardwoods and may provide an option where such pretreatments are not feasible.
|
|
| 2. |
- Schmidt, Hartmut H., et al.
(författare)
-
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
- 2022
-
Ingår i: American Journal of Transplantation. - : John Wiley & Sons. - 1600-6135 .- 1600-6143. ; 22:6, s. 1646-1657
-
Tidskriftsartikel (refereegranskat)abstract
- Hereditary transthyretin-mediated (hATTR) amyloidosis, or ATTRv amyloidosis, is a progressive disease, for which liver transplantation (LT) has been a long-standing treatment. However, disease progression continues post-LT. This Phase 3b, open-label trial evaluated efficacy and safety of patisiran in patients with ATTRv amyloidosis with polyneuropathy progression post-LT. Primary endpoint was median transthyretin (TTR) reduction from baseline. Twenty-three patients received patisiran for 12 months alongside immunosuppression regimens. Patisiran elicited a rapid, sustained TTR reduction (median reduction [Months 6 and 12 average], 91.0%; 95% CI: 86.1%–92.3%); improved neuropathy, quality of life, and autonomic symptoms from baseline to Month 12 (mean change [SEM], Neuropathy Impairment Score, −3.7 [2.7]; Norfolk Quality of Life-Diabetic Neuropathy questionnaire, −6.5 [4.9]; least-squares mean [SEM], Composite Autonomic Symptom Score-31, −5.0 [2.6]); and stabilized disability (Rasch-built Overall Disability Scale) and nutritional status (modified body mass index). Adverse events were mild or moderate; five patients experienced ≥1 serious adverse event. Most patients had normal liver function tests. One patient experienced transplant rejection consistent with inadequate immunosuppression, remained on patisiran, and completed the study. In conclusion, patisiran reduced serum TTR, was well tolerated, and improved or stabilized key disease impairment measures in patients with ATTRv amyloidosis with polyneuropathy progression post-LT (www.clinicaltrials.gov NCT03862807).
|
|
